BioCorRx Inc. (BICX) Form 10-Q — May 15, 2026
BioCorRx Inc. reported a net loss of $859,892 for the three months ended March 31, 2026, driven by operating expenses of $1.17M that outpaced revenue of $214,539. The company’s cash position stands at a critically low $211,911 against a working capital deficit of $7.5 million. The filing includes explicit going-concern language, stating that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve-month period.
Key figures
- Revenue
- 214539
- Revenue Yoy
- 59.0%
- Cash Position
- 211911
- Rd Expense
- 352333
- Grant Income
- 362597
- Shares Outstanding
- 28906559
- Options Outstanding
- 1669075
- Warrants Outstanding
- 4790885
Price after filing
Close on the filing date to close N calendar days later (from $0.49). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.